Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized Phase II Study Comparing Single-Agent Olaparib, Single Agent Cediranib, and the Combination of Cediranib/Olaparib in Women With Recurrent, Persistent or Metastatic Endometrial Cancer

Trial Profile

A Randomized Phase II Study Comparing Single-Agent Olaparib, Single Agent Cediranib, and the Combination of Cediranib/Olaparib in Women With Recurrent, Persistent or Metastatic Endometrial Cancer

Recruiting
Phase of Trial: Phase II

Latest Information Update: 03 Feb 2019

At a glance

  • Drugs Adavosertib (Primary) ; Cediranib (Primary) ; Olaparib (Primary)
  • Indications Adenocarcinoma; Carcinoma; Endometrial cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 09 Nov 2018 Planned number of patients changed from 160 to 120.
    • 17 Sep 2018 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top